Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Accounts Payables: 2012-2025

Historic Accounts Payables for Veracyte (VCYT) over the last 12 years, with Sep 2025 value amounting to $5.5 million.

  • Veracyte's Accounts Payables fell 43.03% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 43.03%. This contributed to the annual value of $8.6 million for FY2024, which is 33.29% down from last year.
  • According to the latest figures from Q3 2025, Veracyte's Accounts Payables is $5.5 million, which was down 51.87% from $11.4 million recorded in Q2 2025.
  • Over the past 5 years, Veracyte's Accounts Payables peaked at $15.7 million during Q1 2025, and registered a low of $5.5 million during Q3 2025.
  • Moreover, its 3-year median value for Accounts Payables was $12.2 million (2024), whereas its average is $11.7 million.
  • In the last 5 years, Veracyte's Accounts Payables soared by 479.76% in 2021 and then slumped by 43.03% in 2025.
  • Over the past 5 years, Veracyte's Accounts Payables (Quarterly) stood at $12.4 million in 2021, then declined by 3.63% to $11.9 million in 2022, then climbed by 8.66% to $12.9 million in 2023, then plummeted by 33.29% to $8.6 million in 2024, then slumped by 43.03% to $5.5 million in 2025.
  • Its Accounts Payables was $5.5 million in Q3 2025, compared to $11.4 million in Q2 2025 and $15.7 million in Q1 2025.